New approaches to the treatment of ALS

Neurology

Volumn 48, Issue 4 SUPPL. 4, 1997, Pages

  Miller, Robert G ^a   Sufit, Robert ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GABAPENTIN; NEURITE PROMOTING FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; PROTEASE NEXIN I; PROTEINASE INHIBITOR; RECOMBINANT SOMATOMEDIN C; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTHRALGIA; ASTHENIA; CONFERENCE PAPER; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; GENE MUTATION; HIRSUTISM; HUMAN; LIVER TOXICITY; MOTOR NEURON DISEASE; OXIDATIVE STRESS; PAIN; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL;

EID: 0030970888     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.4_suppl_4.28s     Document Type: Conference Paper

References (35)

1. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis (ALS). Neurology 1993; 43:1316-1322.
2. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993;16:27-32.
3. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
4. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
5. Rothstein JD. Excitotoxicity hypothesis. Neurology 1996; 47(suppl 2):S19-S26.
6. Brown RH. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments. Ann Neurol 1996;39:147-157.
7. Siddique T, Nijhawan D, Hentati A. Molecular genetic basis of familial ALS. Neurology 1996;47(suppl 2):S27-S35.
8. Pall HS. Motor neurone disease. Rev Clin Gerontol 1995;5: 303-311.
9. Festoff BW. Amyotrophic lateral sclerosis: current and future treatment strategies. Drugs 1996;51:28-44.
10. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250:473-476.
11. Debono M-W, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993;235:283-289.
12. Benavides J, Camelin JC, Mitrani N, et al. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission - II: biochemical properties. Neuropharmacology 1985;24:1085-1092.
13. Hubert JP, Delumeau JC, Glowinski J, Prémont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-267.
14. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel α subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-1060.
15. Estevez AG, Stutzmann J-M, Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur J Pharmacol 1995;280:47-53.
16. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5:1012-1014.
17. Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995;65:643-651.
18. Gurney ME, Curring FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
19. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. J Neurol Sci 1994;124(suppl):96-107.
20. Rowland LP. Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell? [editorial]. N Engl J Med 1994;330: 636-637.
21. Saletu B, Grünberger J, Anderer P, Linzmayer L. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia. Methods Find Exp Clin Pharmacol 1996;18:55-66.
22. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993;124:73-88.
23. Neff NT, Prevette D, Houenou LJ, et al. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 1993;24:1578-1588.
24. Lange DJ, Felice KJ, Festoff BW, et al. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. Neurology 1996;47(suppl 2): S93-S95.
25. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
26. Yan Q, Elliot J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature 1992;360:753-755.
27. Sendtner M, Holtmann B, Kolbeck R, et al. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature 1992;360:757-759.
28. Novikov L, Novikova L, Kellerth JO. Brain-derived neurotrophic factor promotes survival and blocks nitric oxide synthase expression in adult rat spinal motoneurons after ventral root avulsion. Neurosci Lett 1995;200:45-48.
29. BDNF Study Group. Subcutaneous administration of recombinant human methionyl-brain-derived neurotrophic factor (r-meth-huBDNF) in amyotrophic lateral sclerosis [abstract]. Ann Neurol 1995;38:971.
30. Welty DF, Schielke GP, Rothstein JD. Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. Ann Pharmacother 1995;29:1164-1167.
31. Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology [in press].
32. Li L, Wu W, Lin L-F H, Lei M, Oppenheim RW, Houenou LJ. Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neurotrophic factor. Proc Natl Acad Sci USA 1995;92:9771-9775.
33. Mitsumoto H, Olney RK. Drug combination treatment in patients with ALS: current status and future directions. Neurology 1996;47(suppl 2):S103-S107.
34. Munsat TL, Taft J, Jackson IMD, et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 1992;42:1049-1053.
35. Aebischer P, Schleup M, Déglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Med 1996;2:696-699.